AstraZeneca Debt to Equity Ratio 2006-2018 | AZN

Current and historical debt to equity ratio values for AstraZeneca (AZN) over the last 10 years.
AstraZeneca Annual Debt/Equity Ratio
2017 1.07
2016 1.01
2015 0.81
2014 0.55
2013 0.45
2012 0.43
2011 0.40
2010 0.39
2009 0.53
2008 0.74
2007 1.03
2006 0.08
2005 0.09
AstraZeneca Quarterly Debt/Equity Ratio
Q2 2018 1.38
Q1 2018 1.36
Q4 2017 1.07
Q3 2017 1.16
Q2 2017 1.28
Q1 2017 1.18
Q4 2016 1.01
Q3 2016 1.19
Q2 2016 1.14
Q1 2016 0.98
Q4 2015 0.81
Q3 2015 0.63
Q2 2015 0.60
Q1 2015 0.62
Q4 2014 0.55
Q3 2014 0.49
Q2 2014 0.46
Q1 2014 0.48
Q4 2013 0.45
Q3 2013 0.44
Q2 2013 0.44
Q1 2013 0.45
Q4 2012 0.43
Q3 2012 0.49
Q2 2012 0.42
Q1 2012 0.43
Q4 2011 0.40
Q3 2011 0.39
Q2 2011 0.40
Q1 2011 0.43
Q4 2010 0.39
Q3 2010 0.48
Q2 2010 0.46
Q1 2010 0.50
Q4 2009 0.53
Q3 2009 0.58
Q2 2009 0.65
Q1 2009 0.75
Q4 2008 0.74
Q3 2008 0.83
Q2 2008 0.93
Q1 2008 1.02
Q4 2007 1.03
Q3 2007 0.00
Q2 2007 1.04
Q1 2007 0.08
Q4 2006 0.08
Q3 2006 0.08
Q2 2006 0.08
Q1 2006 0.09
Q4 2005 0.09
Q3 2005 0.09
Q2 2005 0.10
Q1 2005 0.08
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $98.732B $22.465B
AstraZeneca PLC is one of the top five pharmaceutical companies in the world based on sales and is a therapeutic leader in cardiovascular, gastrointestinal, oncology, anesthesia including pain management, central nervous system (CNS) and respiratory products. They are engaged in the research, development, manufacture and marketing of ethical (prescription) pharmaceuticals and agricultural products, and the supply of healthcare services.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $347.436B 16.60
Pfizer (PFE) United States $242.341B 14.19
Novartis AG (NVS) Switzerland $190.356B 16.33
Merck (MRK) United States $179.189B 15.82
AbbVie (ABBV) United States $145.249B 14.19
Novo Nordisk (NVO) Denmark $118.145B 18.89
Eli Lilly (LLY) United States $110.019B 20.37
Sanofi (SNY) France $103.584B 13.11
GlaxoSmithKline (GSK) United Kingdom $98.701B 13.18
Bristol-Myers Squibb (BMY) United States $98.007B 17.74